LQDA
Liquidia Corporation · Healthcare
Insiders bought $318K of Liquidia Corporation in the last 12 months
1 insider bought on 1 day.
LQDA over the last year
Largest buyers, last 12 months
LQDA after insider buys
3 months after each buy, from the first price a copier could get.
13 buys since 2018 with 3 months of prices.
Every filing
143 insider filings since 2018, newest first
Michael Kaseta · CFO and COO
Scott Moomaw · Chief Commercial Officer
Jason Adair · Chief Business Officer
Dana Boyle · Chief Accounting Officer
Michael Kaseta · CFO and COO
Sarah Krepp · Chief Human Resource Officer
Rajeev Saggar · Chief Medical Officer
Russell Schundler · General Counsel
Roger Jeffs · CEO
Roger Jeffs · CEO
Michael Kaseta · CFO and COO
Stephen M Bloch · Director
Scott Moomaw · Chief Commercial Officer
Rajeev Saggar · Chief Medical Officer
Sarah Krepp · Chief Human Resource Officer
Raman Singh · Director
Scott Moomaw · Chief Commercial Officer
Russell Schundler · General Counsel
Scott Moomaw · Chief Commercial Officer
Michael Kaseta · CFO and COO
Dana Boyle · Chief Accounting Officer
Jason Adair · Chief Business Officer
Sarah Krepp · Chief Human Resource Officer
Scott Moomaw · Chief Commercial Officer
Michael Kaseta · CFO and COO
Jason Adair · Chief Business Officer
Russell Schundler · General Counsel
Roger Jeffs · CEO
Dana Boyle · Chief Accounting Officer
Rajeev Saggar · Chief Medical Officer
Russell Schundler · General Counsel
Michael Kaseta · CFO and COO
Scott Moomaw · Chief Commercial Officer
Rajeev Saggar · Chief Medical Officer
Russell Schundler · General Counsel
Rajeev Saggar · Chief Medical Officer
Michael Kaseta · CFO and COO
Roger Jeffs · CEO
Paul B Manning · Director
Caligan Partners LP · 10% owner
Roger Jeffs · CEO
Michael Kaseta · CFO and COO
Russell Schundler · General Counsel
Michael Kaseta · CFO and COO
Roger Jeffs · CEO
Jason Adair · Chief Business Officer
Russell Schundler · General Counsel
Scott Moomaw · Chief Commercial Officer
Michael Kaseta · CFO and COO
Rajeev Saggar · Chief Medical Officer
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.